Business
Directorate Change
SkinBioTherapeutics PLC announced that Simon Hewitson, an Executive Director and Chief Operating Officer, will be leaving the company due to personal reasons. The recruitment process for his replacement has already begun. In the interim, CEO Stuart Ashman and Group Finance Director Emily Bertram will manage Hewitson's responsibilities. The company's Chair, Martin Hunt, acknowledged Hewitson's support, particularly with the divisional companies Bio-Tec Solutions and Dermatonics. Disclaimer*
About this update from Skinbiotherapeutics Plc
SkinBioTherapeutics plc ("SkinBioTherapeutics" or "the Company") Directorate Change 14 October 2025 - the Board of Directors of SkinBioTherapeutics, (AIM: SBTX), a life science company focused on skin health, announces that Simon Hewitson, an Executive Director on the Board and Chief Operating Officer of the Group, will be stepping away from the Company on personal grounds. Recruitment for his successor has commenced. In the meantime, his duties are being managed by Stuart Ashman, CEO, and Emily Bertram, Group Finance Director. Martin Hunt, Chair of SkinBioTherapeutics said: "Simon has been a good support to the business, particularly working with our divisional companies, Bio-Tec Solutions and Dermatonics. We wish him and his family well for the future." -Ends- For more information please contact: SkinBioTherapeutics plc Martin Hunt, Chair Stuart J. Ashman, CEO Emily Bertram, Group Finance Director +44 (0) 191 495 7325 Singer Capital Markets (Nominated Adviser & Broker) Philip Davies Sam Butcher Patrick Weaver +44 (0) 020 7496 3000 Vigo Consulting (financial press) Rozi Morris, Melanie Toyne-Sewell +44 (0) 20 7390 0230 [email protected] Notes to Editors About SkinBioTherapeutics plc SkinBioTherapeutics is a life science company focused on skin health. The Group's proprietary platform technology, SkinBiotix ® , is based upon discoveries made by the translational dermatology team at the University of Manchester. The Group's foundation business is targeting the skin healthcare market via five pillars, the most advanced of which are cosmetic skincare (SkinBiotix) and food supplements to modulate the immune system by harnessing the gut-skin axis (AxisBiotix). The cosmetic pillar has a partnership with Croda plc and the SkinBiotix active ingredient, Zenakine™ was launched in April 2025. The Group's first in-house product, AxisBiotix-Ps™, is a food supplement to address the symptoms of mild to moderate psoriasis. The Group is also acting as a consolidator and is making acquisitions in complementary areas such as skin care and cosmetic applications, that also bring new distribution and geographical platforms, and manufacturing capabilities through which it can funnel its in-house pillar products. The Company listed on AIM in April 2017 and is based in Newcastle, UK. For more information, visit: www.skinbiotherapeutics.com .
View stock analysis, news, and events for Skinbiotherapeutics Plc